Dr. Thomas Powles explains standard treatment for metastatic urothelial cancer
Treatment following progression on chemotherapy and an immune checkpoint inhibitor remains an unmet medical need.
Treatment following progression on chemotherapy and an immune checkpoint inhibitor remains an unmet medical need.
“All this is very detailed immunology, I get that, but it sets the stage for what I consider the next evolution of immunotherapy,” says Patrick…
“Our research shows that the identification of these genetic factors, even in geriatric patients, is important for determining targeted treatment and overall patient survival,” says…
“There’s definitely more work to do to confirm these results on a multi-institutional aspect,” says Ryan L. Steinberg, MD.
“This data emphasizes the importance of utilizing the EPI test for risk assessment of high-risk prostate cancer in [African American] men,” concluded the authors.
Results of an exclusive Urology Times survey reveal that more than 70% of respondents said they consider age a relevant factor in the performance of…
In this video, 4 experts discuss the highlights and take-home messages from the 2024 American Urological Association Annual Meeting.
There was a statistically significant reduction in average daily micturition episodes and average daily urgency episodes with vibegron vs placebo.
“What we need is continued work on integrating surgery and systemic therapy,” says Patrick Kenney, MD.
The FDA is set to have a decision regarding the subcutaneous nivolumab formulation on or by February 28, 2025.
Real-world data showed routine use of darolutamide regimens in community urology practice for patients with metastatic hormone-sensitive prostate cancer.